Cerebellopontine angle primary diffuse large B cell (non-Hodgkins) lymphoma mimicking an acoustic schwannoma

2006 ◽  
Vol 60 (3) ◽  
pp. 93-96 ◽  
Author(s):  
M. Kjolby ◽  
K. Müller ◽  
M. Schumacher
Keyword(s):  
B Cell ◽  
Cerebellopontine Angle ◽  
Hodgkins Lymphoma ◽  
Non Hodgkins Lymphoma ◽  
Acoustic Schwannoma ◽  
Large B Cell

scholarly journals Diffuse large B-cell non-Hodgkins lymphoma: R-mini-CHOP or physician's choice dose-adjusted chemotherapy in patients over 80 years old

2017 ◽  
Vol 35 ◽  
pp. 341-341 ◽  
Author(s):  
A. Paschalis ◽  
A. White ◽  
R. Corser ◽  
C. Yeoh ◽  
A. O'Callaghan
Keyword(s):  
B Cell ◽  
Hodgkins Lymphoma ◽  
Non Hodgkins Lymphoma ◽  
Large B Cell

Rituximab Maintenenance Therapy in CD20+ B-Cell Non-Hodgkin-Lymphoma - Results of a Multicenter Prospective Randomised Phase II Study.

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 4704-4704 ◽  
Author(s):  
Mathias Witzens-Harig ◽  
Manfred Hensel ◽  
Johann W. Schmier ◽  
Kai Neben ◽  
Axel Benner ◽  
...  
Keyword(s):  
Maintenance Therapy ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Aggressive Lymphoma ◽  
Pharmacokinetic Data ◽  
Hodgkins Lymphoma ◽  
Rituximab Maintenance ◽  
Mediastinal Lymphoma ◽  
Non Hodgkins Lymphoma

Abstract Clinical and pharmacokinetic data suggest that the effect of rituximab could be improved by prolonged exposure to the drug. To test for this hypothesis we performed a prospective randomized trial of rituximab maintenance therapy in patients with CD20+ B-cell Non-Hodgkins-Lymphoma. After completion of standard treatment patients were randomized to either observation or maintenance therapy with rituximab (375 mg/m2) every 3 months for 2 years. Patients after first line therapy as well as relapse patients were included in the study. Patients with aggressive lymphoma were enrolled if they had achieved a complete response (CR) after initial treatment. Patients with aggressive lymphoma with residual tumor mass were examined with positrone emission tomography (PET) and qualified for randomization if PET showed no signs of tumor activity. Patients with indolent lymphoma qualified for the study if at least a partial response (PR) was achieved. So far 162 patients (pts) with CD20+ B-cell Non-Hodgkins-Lymphoma were enrolled in this trial. Histological subtypes included diffuse large cell lymphoma (69 pts), follicular lymphoma (41 pts), mantle cell lymphoma (18 pts), primary mediastinal lymphoma (15 pts), marginal zone lymphoma (9 pts), Burkitt’s lymphoma (3 pts), immunocytoma (2 pts), primary intestinal lymphoma (1 pt), hairy cell leukemia (1 pt), chronic lymphocytic leukemia (1 pt) and unclassified B-cell lymphoma (2 pts). No severe adverse events were observed during rituximab maintenance therapy. We conclude that rituximab maintenance therapy is feasable, safe and well tolerated in patients with CD20+ B-cell Non-Hodgkins-Lymphoma. Results including event free survival and overall survival for the observation group and for the maintenance therapy group will be presented.

Rituximab maintenenance therapy in CD20+ B-cell non-Hodgkin lymphoma - Interim results of a multicenter prospective randomised phase II study

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 17524-17524 ◽  
Author(s):  
M. Witzens-Harig ◽  
M. Hensel ◽  
J. W. Schmier ◽  
K. Neben ◽  
A. Benner ◽  
...  
Keyword(s):  
Maintenance Therapy ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Aggressive Lymphoma ◽  
Pharmacokinetic Data ◽  
Hodgkins Lymphoma ◽  
Rituximab Maintenance ◽  
Mediastinal Lymphoma ◽  
Non Hodgkins Lymphoma

17524 Background: Clinical and pharmacokinetic data suggest that the effect of rituximab could be improved by prolonged exposure to the drug. Methods: To test for this hypothesis we performed a prospective randomized trial of rituximab maintenance therapy in patients with CD20+ B-cell Non-Hodgkins-Lymphoma. After completion of standard treatment patients were randomized to either observation or maintenance therapy with rituximab (375 mg/m2) every 3 months for 2 years. Patients after first line therapy as well as relapse patients were included in the study. Patients with aggressive lymphoma were enrolled if they had achieved a complete response (CR) after initial treatment. Patients with aggressive lymphoma with residual tumor mass were examined with positrone emission tomography (PET) and qualified for randomization if PET showed no signs of tumor activity. Patients with indolent lymphoma qualified for the study if at least a partial response (PR) was achieved. Results: So far 124 patients (pts) with CD20+ B-cell Non-Hodgkins-Lymphoma were enrolled in this trial. Histological subtypes included diffuse large cell lymphoma (55 pts), follicular lymphoma (24 pts), mantle cell lymphoma (16 pts), primary mediastinal lymphoma (12 pts), marginal zone lymphoma (8 pt), Burkitt’s lymphoma (3 pt), immunocytoma (2 pt), primary intestinal lymphoma (1 pt), hairy cell leukemia (1 pt), chronic lymphocytic leukemia (1 pt) and unclassified B-cell lymphoma (1 pt). No severe adverse events were observed during rituximab maintenance therapy. Results from an interim analysis including event free survival and overall survival for the observation group and for the maintenance therapy group will be presented. Conclusions: We conclude that rituximab maintenance therapy is feasable, effective, safe and well tolerated in patients with CD20+ B-cell Non-Hodgkins-Lymphoma. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document